Efficiency of fixed-ratio combination glucagon-like peptide receptor agonist and basal insulin in type 2 diabetes on different therapeutic regimen

Fixed ratio combination of basal insulin and a glucagon-like peptide-1 receptor agonist (GLP-1RA) offers another option to patients with type 2 diabetes (T2DM) with inadequate glycemic control, especially for those desiring simplified method of treatment intensification in order to improve adherence. There are two types of fixed-ratio combinations: insulin degludec/liraglutide (iDergLira) and insulin glargine/lixisenatide (iGlarLixi). The aim of this study was to evaluate efficacy of intesifying the treatment with fixed ratio combination basal insulin and GLP-1 RA in patients inadequatly controlled on different therapeutic regimen. The study included 200 patients with uncontrolled T2DM, who were divided into four equal groups based on the therapeutic regimen before study: oral diabetic agents or metformin and basal insulin or metformin and GLP 1RA or premix insulin. Our results showed that fixed ratio combination showed better efficiency of on glycemic control in patients previously treated with oral agents and premix insulin, while patients previously treated with premix insulin have had the greatest benefit regarding weight change. We found no difference in glycemic control between iDegLira and iGlarLixi, but significant difference in weight reduction between iDegLira and iGlarLixi.